<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333031</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00082272</org_study_id>
    <nct_id>NCT03333031</nct_id>
  </id_info>
  <brief_title>A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies</brief_title>
  <official_title>A Phase I Study of HS-196, an HSP90 Inhibitor-linked Near Infrared Probe for Detection of Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Lyerly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      HS-196 is near infrared red (NIR)-tethered HSP90 inhibitor for clinical imaging of selective&#xD;
      tumor binding. HS-196 consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP&#xD;
      binding domain connected by a linker to a contrast agent (near infrared (NIR) dye) that can&#xD;
      be used for imaging. HS-196 can freely enter tumor cells to selectively bind Hsp90. Due to&#xD;
      the the NIR dye, HS-196 accumulation in the malignant cells allows for specific visualization&#xD;
      of tumors within the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The product to be tested under this IND, HS-196, is a tumor imaging agent.&#xD;
&#xD;
      Hsp90 (heat shock protein 90) is a chaperone protein that aids in the folding, stabilization,&#xD;
      and degradation of cellular proteins and is found in virtually all living organisms. Cancer&#xD;
      cells in particular have high expression of Hsp90. Hsp90 has three structural domains&#xD;
      including an N-terminal domain that contains an ATP binding site. Small molecule inhibitors&#xD;
      of HSP90 (Hsp90i) can selectively and competitively to the Hsp90 ATP binding domain. HS-196&#xD;
      consists of a HSP90 inhibitor that binds competitively to the Hsp90 ATP binding domain&#xD;
      connected by a linker to a contrast agent (near infrared (NIR) dye) that can be used for&#xD;
      imaging. HS-196 can freely enter tumor cells to selectively bind Hsp90. Due to the the NIR&#xD;
      dye, HS-196 accumulation in the malignant cells allows for specific visualization of tumors&#xD;
      within the body.&#xD;
&#xD;
      HS-196 will be used in this investigation for the imaging of solid tumors The objectives of&#xD;
      the study are to determine the dose of HS-196 that achieves the greatest ratio of tumor to&#xD;
      normal tissue fluorescence in patients with malignancy, the safety of HS-196 administration&#xD;
      in patients with malignancy, the average radiant efficiency in resected tumors following&#xD;
      HS-196 administration, the localization of the HS-196 by microscopy of tumor slices, and the&#xD;
      PK metrics of HS-196 when administered to patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2018</start_date>
  <completion_date type="Anticipated">August 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluorescence</measure>
    <time_frame>1 day</time_frame>
    <description>Ratio of tumor to normal tissue fluorescence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of AEs</measure>
    <time_frame>1 month</time_frame>
    <description>Safety of HS-196 administration in patients with malignancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiant Efficiency</measure>
    <time_frame>1 day</time_frame>
    <description>The average radiant efficiency in resected tumors following HS-196 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HS-196 Localization</measure>
    <time_frame>1 day</time_frame>
    <description>Localization of the HS-196 by microscopy of tumor slices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma concentration Cmax</measure>
    <time_frame>1 week</time_frame>
    <description>PK metrics of HS-196 when administered IV to patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve AUC</measure>
    <time_frame>1 week</time_frame>
    <description>PK metrics of HS-196 when administered IV to patients</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HS-196</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HS-196 will be administered intravenously as a single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HS-196</intervention_name>
    <description>HS-196 will be administered intravenously as a single dose</description>
    <arm_group_label>HS-196</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For Dose escalation and recommended dose phases:&#xD;
&#xD;
          -  Diagnosis of a solid malignancy, stage I-IV, with planned surgical resection or&#xD;
             biopsy.&#xD;
&#xD;
        For Expansion phase:&#xD;
&#xD;
          -  Patients with mammographically detected breast nodules with planned surgical resection&#xD;
             or biopsy.&#xD;
&#xD;
        For All phases:&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
          -  Estimated life expectancy &gt; 3 months&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is&#xD;
             acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR &lt;1.5,&#xD;
             PTT &lt;1.5X ULN&#xD;
&#xD;
          -  Adequate renal and hepatic function, with serum creatinine &lt; 1.5 mg/dL, bilirubin &lt;&#xD;
             1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT&#xD;
             and AST ≤ 2.5 x upper limit of normal or if liver metastases are present &lt; 5 x upper&#xD;
             limit of normal.&#xD;
&#xD;
          -  Female patients must be of non-child-bearing potential or use effective contraception,&#xD;
             e.g., use of oral contraceptives with an additional barrier method (since the study&#xD;
             drug may impair the effectiveness of oral contraceptives), double barrier methods&#xD;
             (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera,&#xD;
             partner vasectomy, total abstinence, and willing to continue the effective&#xD;
             contraception method for 30 days after the last dose of study drug;&#xD;
&#xD;
          -  Ability to understand and provide signed informed consent that fulfills Institutional&#xD;
             Review Board's guidelines.&#xD;
&#xD;
          -  Ability to return to Duke University Medical Center for adequate follow-up, as&#xD;
             required by this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious chronic or acute illness considered by the P.I. to constitute an unwarranted&#xD;
             high risk for investigational drug treatment.&#xD;
&#xD;
          -  Medical or psychological impediment to probable compliance with the protocol.&#xD;
&#xD;
          -  Asthma under medical management&#xD;
&#xD;
          -  Uncontrolled high blood pressure&#xD;
&#xD;
          -  Presence of a known active acute or chronic infection including HIV or viral hepatitis&#xD;
             (Hepatitis B and C)).&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Kim Lyerly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Morse, MD</last_name>
    <phone>919 684 5705</phone>
    <email>michael.morse@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Hobeika</last_name>
    <phone>919 684 6112</phone>
    <email>AMY.HOBEIKA@DUKE.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Morse, MD</last_name>
      <phone>919-684-5705</phone>
      <email>michael.morse@duke.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Herbert Lyerly</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>imaging agent</keyword>
  <keyword>HSP90</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

